Epirus fixes on Europe for biosimilar base business
This article was originally published in Scrip
Executive Summary
Boston-based biosimilar developer Epirus Biopharmaceuticals, which recently sewed up an alliance with China's Livzon Mabpharm, is keen to moor its business in Europe while pursuing growth in key emerging markets.